Merus N.V. announced on September 30, 2024, that the first patient has been dosed in its Phase 3 LiGeR-HN1 trial. This trial is evaluating the efficacy and safety of petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with pembrolizumab.
The study focuses on the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients in the trial will be randomized to receive either petosemtamab plus pembrolizumab or pembrolizumab monotherapy.
Advancing petosemtamab into a pivotal Phase 3 trial represents a crucial step in its development. This milestone underscores Merus's commitment to bringing innovative therapies to patients with difficult-to-treat cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.